Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

amikacin

  • Differential <em>In Vitro</em> Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved <span class="named-content genus-species" id="named-content-1">Mycobacterium abscessus</span>
    Experimental Therapeutics
    Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus

    Current treatment options for lung disease caused by Mycobacterium abscessus complex infections have limited effectiveness. To maximize the use of existing antibacterials and to help inform regimen design for treatment, we assessed the in vitro bactericidal activity of single drugs against actively multiplying and net nonreplicating...

    Jin Lee, Nicole Ammerman, Anusha Agarwal, Maram Naji, Si-Yang Li, Eric Nuermberger
  • Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span> in a Dynamic <em>In Vitro</em> Hollow-Fiber Infection Model
    Pharmacology
    Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model

    Given that aminoglycosides, such as amikacin, may be used for multidrug-resistant Pseudomonas aeruginosa infections, optimization of therapy is paramount for improved treatment outcomes. This study aims to investigate the pharmacodynamics of different simulated intravenous amikacin doses on susceptible P....

    Aaron J. Heffernan, Fekade B. Sime, Derek S. Sarovich, Michael Neely, Yarmarly Guerra-Valero, Saiyuri Naicker, Kyra Cottrell, Patrick Harris, Katherine T. Andrews, David Ellwood, Steven C. Wallis, Jeffrey Lipman, Keith Grimwood, Jason A. Roberts
  • Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing <span class="named-content genus-species" id="named-content-1">Klebsiella pneumoniae</span>
    Pharmacology
    Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae

    Resistance to polymyxin antibiotics is increasing. Without new antibiotic classes, combination therapy is often required. We systematically investigated bacterial killing with polymyxin-based combinations against multidrug-resistant (including polymyxin-resistant), carbapenemase-producing Klebsiella pneumoniae. Monotherapies and double- and triple-combination...

    Su Mon Aye, Irene Galani, Heidi Yu, Jiping Wang, Ke Chen, Hasini Wickremasinghe, Ilias Karaiskos, Phillip J. Bergen, Jinxin Zhao, Tony Velkov, Helen Giamarellou, Yu-Wei Lin, Brian T. Tsuji, Jian Li
  • Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions
    Clinical Therapeutics
    Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions

    The aim of this work was to evaluate the pharmacokinetics of amikacin in Mexican patients with different renal functions receiving once-daily dosing regimens and the influence of clinical and demographical covariates that may influence the optimization of this antibiotic. A prospective study was performed in a total of 63 patients with at least one determination of amikacin plasma concentration. Population pharmacokinetic (PK)...

    Norma A. Aréchiga-Alvarado, Susanna E. Medellín-Garibay, Rosa del C. Milán-Segovia, Arturo Ortiz-Álvarez, Martín Magaña-Aquino, Silvia Romano-Moreno
  • Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy
    Pharmacology
    Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy

    The aim was to assess the appropriateness of recommended regimens for empirical MIC coverage in critically ill patients with open-abdomen and negative-pressure therapy (OA/NPT). Over a 5-year period, every critically ill patient who received amikacin and who underwent therapeutic drug monitoring (TDM) while being treated by OA/NPT was retrospectively included. A population pharmacokinetic (PK) modeling was performed considering the...

    Cédric Carrié, Faustine Delzor, Stéphanie Roure, Vincent Dubuisson, Laurent Petit, Mathieu Molimard, Dominique Breilh, Matthieu Biais
  • Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span>
    Mechanisms of Action: Physiological Effects
    Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa

    In the present study, we employed untargeted metabolomics to investigate the synergistic killing mechanism of polymyxin B in combination with an aminoglycoside, amikacin, against a polymyxin-susceptible isolate of Pseudomonas aeruginosa, FADDI-PA111 (MIC = 2 mg/liter for both polymyxin B and amikacin), and a polymyxin-resistant Liverpool epidemic strain (LES), LESB58...

    Maytham Hussein, Mei-Ling Han, Yan Zhu, Qi Zhou, Yu-Wei Lin, Robert E. W. Hancock, Daniel Hoyer, Darren J. Creek, Jian Li, Tony Velkov
  • Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize <em>A Priori</em> Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients
    Pharmacology
    Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients

    Amikacin is commonly used for probabilistic antimicrobial therapy in critically ill patients with sepsis. Its narrow therapeutic margin makes it challenging to determine the right individual dose that ensures the highest efficacy target attainment rate (TAR) in this setting. This study aims to develop a new initial dosing approach for amikacin by optimizing the a priori TAR in this population.

    Clément Boidin, Laurent Bourguignon, Sabine Cohen, Claire Roger, Jean-Yves Lefrant, Jason A. Roberts, Bernard Allaouchiche, Alain Lepape, Arnaud Friggeri, Sylvain Goutelle
  • A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy?
    Clinical Therapeutics
    A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy?

    Increasing bacterial resistance and poor patient adherence rates limit the effectiveness of conventional antibiotic therapies for urinary tract infection (UTI). The objective of this study was to investigate whether a single aminoglycoside dose adequately treated UTI.

    Kellie J. Goodlet, Fatima Z. Benhalima, Michael D. Nailor
  • Emergence of <span class="named-content genus-species" id="named-content-1">Klebsiella pneumoniae</span> Harboring the <em>aac(6ʹ)-Ian</em> Amikacin Resistance Gene
    Letter to the Editor
    Emergence of Klebsiella pneumoniae Harboring the aac(6ʹ)-Ian Amikacin Resistance Gene
    Paloma Troyano-Hernáez, Almudena Gutiérrez-Arroyo, Rosa Gómez-Gil, Jesús Mingorance, Fernando Lázaro-Perona
  • Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis
    Pharmacology
    Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis

    Practitioners commonly use amikacin in patients with cystic fibrosis. Establishment of the pharmacokinetics of amikacin in adults with cystic fibrosis may increase the efficacy and safety of therapy.

    Sílvia M. Illamola, Hoa Q. Huynh, Xiaoxi Liu, Zubin N. Bhakta, Catherine M. Sherwin, Theodore G. Liou, Holly Carveth, David C. Young

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596